Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boost for EU materials technology sector:

This article was originally published in Clinica

Executive Summary

Materials technology, a subject area that is critical to the future design of medical devices especially given growing environmental pressures, is to benefit from a new boost in the EU. The European Commission had agreed to support the chemical and biotechnology sector organisations, CEFIC and EuropaBio, in launching a Technology Platform on Sustainable Chemistry. This to establish a long-standing public-private partnership to increase investment on research and innovation and boost European competitiveness in this sector. Europe is a world leader in chemical products, holding 28% of the market, but its proportion of global trade has dropped by 4% over the last decade. As well as materials technology, the platform will address industrial biotechnology, and reaction and process design.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel